Simply Wall St
4 min read
In This Article:
The European market has shown resilience with the pan-European STOXX Europe 600 Index rising by 0.90%, buoyed by a slowdown in inflation and easing monetary policy from the European Central Bank. As investors navigate these evolving conditions, penny stocks—often representing smaller or newer companies—continue to capture interest for their potential growth at accessible price points. Despite being an outdated term, penny stocks remain relevant as they can offer opportunities for those seeking to invest in financially strong companies with promising prospects.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
Mistral Iberia Real Estate SOCIMI (BME:YMIB) |
€1.01 |
€22M |
★★★★★☆ |
|
KebNi (OM:KEBNI B) |
SEK1.996 |
SEK541.22M |
★★★★★★ |
|
Angler Gaming (NGM:ANGL) |
SEK3.61 |
SEK270.7M |
★★★★★★ |
|
Cellularline (BIT:CELL) |
€2.95 |
€62.22M |
★★★★★☆ |
|
Fondia Oyj (HLSE:FONDIA) |
€4.78 |
€17.87M |
★★★★★★ |
|
Abak (WSE:ABK) |
PLN4.00 |
PLN10.78M |
★★★★★★ |
|
Bredband2 i Skandinavien (OM:BRE2) |
SEK2.38 |
SEK2.28B |
★★★★☆☆ |
|
Hifab Group (OM:HIFA B) |
SEK3.62 |
SEK220.24M |
★★★★★★ |
|
Deceuninck (ENXTBR:DECB) |
€2.175 |
€300.29M |
★★★★★★ |
|
Netgem (ENXTPA:ALNTG) |
€0.936 |
€31.34M |
★★★★★★ |
Click here to see the full list of 447 stocks from our European Penny Stocks screener.
Let’s dive into some prime choices out of the screener.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: genOway Société anonyme is a biotechnology company that develops and commercializes custom genetically modified mouse, rat, and cell line models globally, with a market cap of €31.44 million.
Operations: The company’s revenue is derived entirely from its biotechnology segment, amounting to €27.53 million.
Market Cap: €31.44M
genOway Société anonyme, with a market cap of €31.44 million, has shown consistent revenue growth, reporting €22.06 million in sales for 2024, up from €20.05 million the previous year. The company maintains strong financial health with short-term assets exceeding both its short and long-term liabilities and a satisfactory net debt to equity ratio of 3.4%. Despite not outperforming the biotech industry in earnings growth last year, genOway’s profitability has improved over five years at an impressive annual rate of 67.1%, supported by high-quality earnings and stable weekly volatility at 6%.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Kudelski SA, with a market cap of CHF67.34 million, offers digital access and security solutions for digital television and interactive applications across Switzerland, the United States, France, Germany, Austria, and other international markets.